UPDATE: Piper Jaffray Initiates Coverage on Alexza Pharmaceuticals to Neutral Rating, $5 PT
Posted on January 04, 2013 at 09:59 AM EST
In a report published Friday, Piper Jaffray & Co. initiated coverage on Alexza Pharmaceuticals (NASDAQ: ALXA ) with a Neutral rating and $5.00 price target. Piper Jaffray noted, “We are initiating coverage on Alexza with a Neutral rating and 12-month price target of $5. Alexza reformulates drugs for pulmonary delivery